A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer

Ding,Cuimin; Li,Ruijuan; Peng,Jingcui; Li,Shengmian; Guo,Zhanjun

doi:10.3892/etm.2012.469

A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer

Authors:
- Cuimin Ding
- Ruijuan Li
- Jingcui Peng
- Shengmian Li
- Zhanjun Guo
View Affiliations

Affiliations: Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China, Department of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P.R. China
Published online on: February 3, 2012 https://doi.org/10.3892/etm.2012.469
Pages: 689-692

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

microRNAs (miRNAs) bind to the 3' untranslated regions (UTRs) of messenger RNAs, where they interfere with translation of genes that regulate cell differentiation, apoptosis and tumourigenesis. The histone methyltransferase SET8 has been reported to methylate TP53 and regulate genomic stability. We analysed a single nucleotide polymorphism (rs16917496) within the miR-502 miRNA seed region at the 3' UTR of SET8 in small-cell lung cancer (SCLC) patients. The SET8 CC+CT genotype was identified to be independently associated with longer survival in SCLC patients by multivariate analysis (relative risk, 0.453; 95% CI 0.217-0.944; p=0.035). The analysis of genetic polymorphisms in miRNA binding sites may help to identify patient subgroups at high risk of poor outcome.

View Figures

View References

1.	Adjei AA, Marks RS and Bonner JA: Current guidelines for the management of small cell lung cancer. Mayo Clin Proc. 74:809–816. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Simon GR and Wagner H: For the American College of Chest Physicians. Small cell lung cancer. Chest. 123(Suppl): 259S–271S. 2003. View Article : Google Scholar : PubMed/NCBI
3.	National Comprehensive Cancer Network: National Comprehensive Cancer Network practice guidelines in oncology v. 1.2007: small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdfuri. Accessed January 9, 2007.
4.	Hyde L, Yee J, Wilson R and Panto ME: Cell type and the natural history of lung cancer. JAMA. 193:52–54. 1965. View Article : Google Scholar : PubMed/NCBI
5.	Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B and Hansen HH: Long term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years – an analysis of 1,714 consecutive patients. J Clin Oncol. 13:1215–1220. 1995.PubMed/NCBI
6.	Rawson NS and Peto J: An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 61:597–604. 1990. View Article : Google Scholar : PubMed/NCBI
7.	Knez L, Sodja E, Kern I, Košnik M and Cufer T: Predictive value of multidrug resistance protein, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review. Lung Cancer. 72:271–279. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Kin YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y and Ochiai A: Expression of the breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer. 65:105–111. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicated that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Zeng Y, Yi R and Cullen BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA. 100:9779–9784. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Zeng Y, Wagner EJ and Cullen BR: Both natural and designed microRNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 9:1327–1333. 2002. View Article : Google Scholar : PubMed/NCBI
14.	Chin LJ, Ratner E, Leng S, et al: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 68:8535–8540. 2008.PubMed/NCBI
15.	Brendle A, Lei H, Brandt A, Johansson R, Enquist K, Henriksson R, Hemminki K, Lenner P and Försti A: Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis. 29:1394–1399. 2008. View Article : Google Scholar : PubMed/NCBI
16.	Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M and Shen SH: Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res. 35:4535–4541. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Forsti A, Hemminki K, Canzian F and Landi S: Polymorphisms within microRNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 29:579–584. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Saunders MA, Liang H and Li W-H: Human polymorphism at microRNA and microRNA target sites. Proc Natl Acad Sci USA. 9:3300–3305. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Gao Y, He Y, Ding J, et al: An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 30:2064–2069. 2009.PubMed/NCBI
20.	Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, Erdjument-Bromage H, Tempst P, Simon JA and Zhang Y: Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol. 12:1086–1099. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P, Tempst P, Steward R, Lis JT, Allis CD and Reinberg D: PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell. 9:1201–1213. 2002. View Article : Google Scholar : PubMed/NCBI
22.	Wu S, Wang W, Kong X, Congdon LM, Yokomori K, Kirschner MW and Rice JC: Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression. Genes Dev. 24:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An miR-502-binding site single-nucleotide polymorphism in the 3′-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res. 19:6292–6300. 2009.
24.	Guo Z, Wu C, Wang X, Wang C, Zhang R and Shan B: A polymorphism at the miR-502 binding site in the 3’-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome. Int J Cancer. Nov 18–2011. View Article : Google Scholar : (E-pub ahead of print).
25.	Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E and Gozani O: Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 27:636–46. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Merritt WM, Lin YG, Han LY, et al: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 359:2641–2650. 2008. View Article : Google Scholar : PubMed/NCBI